Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 641-660
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.641
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.641
Figure 1 Overall and disease-free survival.
A: The overall survival curves for each stage are shown; B: The overall survival significantly differed between patients with stage ≤ IIB (blue line) and those with stage ≥ IIIA (red line) disease (P = 0.0080); C: Disease-free survival curves for each stage are shown; D: There was a significant difference in the disease-free survival of patients with stage ≤ IIB (blue line) and patients with stage ≥ IIIA (red line) disease (P = 0.0054).
Figure 2 The median overall and disease-free survival.
A: The median overall survival of the 11 deceased patients was 1.66 years (0.16–3.36 years); B: The median disease-free interval of the 15 recurrent patients was 0.79 years (0.12–4.01 years).
Figure 3 Comprehensive flowchart of important points in our patients.
Important points (e.g., preoperative diagnosis, surgical treatment, histopathological assessments, stage according to the tumor-node-metastasis classification and prognosis) are summarized. The final stages in each case are shown in parentheses. The outcomes in each case are also shown in parentheses (dead or alive). *Cases with invasive findings of the lymphoid duct and/or nerve plexuses on the histopathological assessment. †Cases with a positive margin at the surgical cut end of the biliary tract. CRT: Chemoradiotherapy; ENBD: Extrahepatic bile duct resection; LC: Laparoscopic cholecystectomy; LN: Lymph node.
- Citation: Kamada Y, Hori T, Yamamoto H, Harada H, Yamamoto M, Yamada M, Yazawa T, Tani M, Sato A, Tani R, Aoyama R, Sasaki Y, Zaima M. Surgical treatment of gallbladder cancer: An eight-year experience in a single center. World J Hepatol 2020; 12(9): 641-660
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/641.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.641